Mereo BioPharma Group PLC (LON:MPH) fell 4.1% on Friday . The stock traded as low as GBX 46.45 ($0.57) and last traded at GBX 46.50 ($0.57), 3,000 shares changed hands during trading. An increase of 1,028% from the average session volume of 266 shares. The stock had previously closed at GBX 48.50 ($0.60).
The company has a market capitalization of $157.50 million and a PE ratio of -1.19. The company has a debt-to-equity ratio of 80.53, a current ratio of 1.02 and a quick ratio of 0.94. The company has a 50-day moving average of GBX 46.11 and a two-hundred day moving average of GBX 29.87.
Mereo BioPharma Group (LON:MPH) last released its earnings results on Tuesday, June 16th. The company reported GBX (39) (($0.48)) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of GBX (27.50) (($0.34)) by GBX (11.50) (($0.14)).
Mereo BioPharma Group Company Profile (LON:MPH)
Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.
See Also: Buyback
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.